Ori Biotech Ltd., a leader in cell and gene therapy (CGT) manufacturing technology, has shared details of its strategic expansion plan following its $100 million Series B funding round in January 2022, including adding key expertise and personnel and new facilities globally in order to rapidly transition into the launch of its innovative cell and gene therapy (CGT) manufacturing platform.
“Our recent Series B funding has enabled us to continue to invest in rapid expansion in preparation for full commercial launch. This ambition has also required us to bring new expertise into the business as well as expand our physical footprint in the U.S. and UK,” said Jason C. Foster, CEO, Ori Biotech. “We have added significant expertise to our senior team and are opening two new facilities that will jointly enable us to extend our leadership position in the industrialization of personalized medicines.”
